Form 4: Eton Pharmaceuticals Executive Receives Stock Grant
Insider Transaction (Form 4)
Ipek Erdogan-Trinkaus, Chief Commercial Officer of Eton Pharmaceuticals, Inc., received 80,000 shares of common stock on July 31, 2026.
Summary
- Grant/award: acquired 80,000 Common Stock on July 31, 2026; holds 80,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ipek Erdogan-Trinkaus — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-31 | Grant/award | Common Stock | 80,000 | — | — | 80,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-31 | Grant/award (80,000 shares) |
Keywords
insider transaction, Form 4, ETON, Eton Pharmaceuticals, Inc., neutral, Ipek Erdogan-Trinkaus
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.